Media Centre
The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public.
To access, please confirm that you are an accredited member of the press.
I hereby confirm that I am an accredited member of the press
Press Releases
01, February, 2022
BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) Authorised in Great Britain for the Maintenance Treatment of Schizophrenia in Adults
08, September, 2021
NICE backs Janssen’s Erleada®▼ (apalutamide) for Hormone-Sensitive Metastatic and Hormone-Relapsed Non-Metastatic Prostate Cancer
29, January, 2021
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
16, November, 2020
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
08, September, 2020
Biopharma Leaders Unite To Stand With Science
Quick Links
FOLLOW US
Janssen UK
@JanssenUK
-
In the UK, around 10,300 people are diagnosed with bladder cancer every year. Please take the time to know the sign… https://t.co/6jQf8j1eSD
2 days 14 hours ago